- Home
- IRON vs LIVN Comparison
IRON vs LIVN Comparison
Compare IRON & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IRON
- LIVN
- Stock Information
- Founded
- IRON 2017
- LIVN 1987
- Country
- IRON United States
- LIVN United Kingdom
- Employees
- IRON N/A
- LIVN N/A
- Industry
- IRON Biotechnology: Pharmaceutical Preparations
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IRON Health Care
- LIVN Health Care
- Exchange
- IRON Nasdaq
- LIVN Nasdaq
- Market Cap
- IRON 1.9B
- LIVN 2.2B
- IPO Year
- IRON N/A
- LIVN 1993
- Fundamental
- Price
- IRON $42.17
- LIVN $35.58
- Analyst Decision
- IRON Strong Buy
- LIVN Buy
- Analyst Count
- IRON 10
- LIVN 7
- Target Price
- IRON $83.80
- LIVN $60.29
- AVG Volume (30 Days)
- IRON 608.5K
- LIVN 772.6K
- Earning Date
- IRON 05-08-2025
- LIVN 05-07-2025
- Dividend Yield
- IRON N/A
- LIVN N/A
- EPS Growth
- IRON N/A
- LIVN 262.50
- EPS
- IRON N/A
- LIVN 1.16
- Revenue
- IRON N/A
- LIVN $1,253,437,000.00
- Revenue This Year
- IRON N/A
- LIVN $5.79
- Revenue Next Year
- IRON N/A
- LIVN $5.35
- P/E Ratio
- IRON N/A
- LIVN $30.67
- Revenue Growth
- IRON N/A
- LIVN 8.66
- 52 Week Low
- IRON $25.64
- LIVN $32.48
- 52 Week High
- IRON $68.73
- LIVN $64.48
- Technical
- Relative Strength Index (RSI)
- IRON 42.98
- LIVN 40.50
- Support Level
- IRON $39.20
- LIVN $32.65
- Resistance Level
- IRON $41.41
- LIVN $35.89
- Average True Range (ATR)
- IRON 4.37
- LIVN 1.91
- MACD
- IRON 0.09
- LIVN 0.05
- Stochastic Oscillator
- IRON 54.14
- LIVN 42.70
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.